FLT3 and acute myeloid leukemia: The drug was recently approved by the FDA on the basis of the randomized, placebo-controlled phase III RATIFY trial (Randomized AML Trial In FLT3 in patients less than 60 Years old) conducted in younger (18–59 years old) newly diagnosed AML patients with anFLT3-ITD orFLT3-tyrosine kinase domain (FLT3-TKD) mutation65,66.